Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).

Marie Reeberg SassAndreas Aalkjær DanielsenOle Köhler-ForsbergHeidi StorgaardFilip K Krag KnopMette Ødegaard NielsenAnders Mikael SjödinOle MorsChristoph U CorrellClaus EkstrømMaj VinbergJimmi NielsenTina VilsbøllAnders Fink-Jensen

Published in: BMJ open (2023)

NCT04892199.

Keyphrases

study protocol
clinical trial
double blind
placebo controlled
spectrum disorder
open label
phase ii
randomized controlled trial
phase iii
bipolar disorder
newly diagnosed
rectal cancer
chemotherapy induced